Search research articles
Contact Us
Filters
Showing results (171-180 of 192) with videos related to
Page
of 20
Sort By:
Journal of Neuroendocrinology
|
May 16, 2024
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force
Anna Koumarianou, Pier Luigi Filosso, Lisa Bodei, et al.
Communications Medicine
|
July 6, 2026
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer
Christoph Schultheiß, Brenda Besemer, Edith Willscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)
Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca, et al.
Nature Communications
|
April 4, 2026
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial
Jaume Capdevila, Jorge Hernando, Javier Molina-Cerillo, et al.
Translational Oncology
|
May 19, 2020
Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma
Lucía Trilla-Fuertes, Ismael Ghanem, Joan Maurel, et al.
The Oncologist
|
February 25, 2025
Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study
Maribel Del Olmo-García, Lorena Hernandez-Rienda, Rocio Garcia-Carbonero, et al.
The Lancet. Oncology
|
December 10, 2020
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Renu R Bahadoer, Esmée A Dijkstra, Boudewijn van Etten, et al.
Neuroendocrinology
|
January 28, 2021
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Angela Lamarca, et al.
The Oncologist
|
May 25, 2026
Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort
Pau Mascaró-Baselga, José Miguel Rodellar Sanz, Tiago Nunes, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 192) with videos related to
Sort By:
Page
of 20
Journal of Neuroendocrinology
|
May 16, 2024
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force
Anna Koumarianou, Pier Luigi Filosso, Lisa Bodei, et al.
Communications Medicine
|
July 6, 2026
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer
Christoph Schultheiß, Brenda Besemer, Edith Willscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)
Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca, et al.
Nature Communications
|
April 4, 2026
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial
Jaume Capdevila, Jorge Hernando, Javier Molina-Cerillo, et al.
Translational Oncology
|
May 19, 2020
Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma
Lucía Trilla-Fuertes, Ismael Ghanem, Joan Maurel, et al.
The Oncologist
|
February 25, 2025
Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study
Maribel Del Olmo-García, Lorena Hernandez-Rienda, Rocio Garcia-Carbonero, et al.
The Lancet. Oncology
|
December 10, 2020
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Renu R Bahadoer, Esmée A Dijkstra, Boudewijn van Etten, et al.
Neuroendocrinology
|
January 28, 2021
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Angela Lamarca, et al.
The Oncologist
|
May 25, 2026
Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort
Pau Mascaró-Baselga, José Miguel Rodellar Sanz, Tiago Nunes, et al.
Page
of 20